product launch
BillionToOne, UCSD Partner to Assess New Liquid Biopsy Assays in Lung Cancer
Investigators are evaluating the firm's tumor profiling and treatment response monitoring assays and expect initial results in a few months.
The firm announced the new test, Guardant360 Response, alongside its launch of its Guardant360 TissueNext tumor tissue genomic profiling product.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More
On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology.
Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.